Infectious Disease

Messenger RNA vaccines lower the risk of asymptomatic infections

March 28, 2021

1 min read

Source / information

Published by:

Disclosure:
Tande does not report any relevant financial information. In the study you will find all relevant financial information from all other authors.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Participants who received two doses of a messenger RNA COVID-19 vaccine tested 80% less positive for asymptomatic SARS-CoV-2, according to clinical trial results published in Clinical Infectious Diseases.

Even after one dose, the risk of asymptomatic infection was reduced by 79%, researchers reported. The two US-approved messenger RNA vaccines are manufactured by Pfizer-BioNTech and Moderna.

Aaron Tande Pullquote

“Because people are routinely cared for and cared for, if they have a pre-procedure test protocol like us, they can have peace of mind as these vaccines reduce the likelihood of infection for these patients.” Aaron J. Tande, MD, Healio said, an advisor in the Infectious Disease Department and Associate Professor of Medicine at the Mayo Clinic College of Medicine.

“For the broader COVID-19 landscape, we believe a good proportion – some studies have estimated 50% of infections – come from people who are asymptomatic or presymptomatic. This suggests that the vaccines can not only prevent serious illness, but also prevent future human transmissions [who] are asymptomatic because they are simply less likely to be infected, ”said Tande.

Tande and colleagues carried out a retrospective cohort study on asymptomatic adult patients in whom a total of 48,333 pre-procedural SARS-CoV-2 screening tests were carried out from December 17, 2020 to February 8, 2021. They analyzed the RR of a positive SARS-CoV-2 test in asymptomatic people who had received a vaccine dose compared to people who had not yet been vaccinated.

A positive SARS-CoV-2 test result was found in 42 (1.4%) of the 3,006 tests for vaccinated patients and 1,436 (3.2%) of the 45,327 tests for non-vaccinated patients (RR = 0.44; 95% CI , 0.33-). 0.6). The risk of asymptomatic SARS-CoV-2 infection in people was more than 10 days after their first dose (RR = 0.21; 95% CI, 0.12-0.37) and more than 0 days after their second Dose (RR = 0.2; 95) lower% CI, 0.09-0.44) compared to non-vaccinated people.

Tande said more studies are needed to look at the reduction in the spread of COVID-19 over longer periods of time after vaccination.

“We need to do bigger studies to confirm this and examine certain subsets of patients. Do immunocompromised people get the same results? “Said Tande.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles